



VALEO PHARMA™

**PRESS RELEASE
FOR IMMEDIATE DISTRIBUTION**

VALEO PHARMA HAS SUBMITTED HESPERCO™ NATURAL PRODUCT LICENSE APPLICATION FOR APPROVAL TO HEALTH CANADA

- **Hesperco™ capsules can be taken to support immune system**
- **Valeo Pharma enters into agreement with Ingenew Pharma Inc.**

MONTREAL, QUEBEC , August 24, 2020 – [Valeo Pharma Inc.](#) (CSE:VPH, FSE:VP2) (“Valeo” or the “Company”), a Canadian specialty pharmaceutical company, announced today that it has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, Hesperco™. Hesperco™ capsules contain a powerful antioxidant that can be taken for immune system support.

In April 2020, Valeo entered into a collaboration and licensing agreement with Ingenew Pharma Inc. (“Ingenew”) for the development, manufacture and commercialization of Hesperco™. Ingenew is responsible for providing clinical and scientific data to support the market positioning, commercial and communication campaigns for Hesperco™.

“Pending Health Canada’s approval, we are poised to proceed with the commercialization of Hesperco™ capsules”, said Steve Saviuk, President and CEO. “ Ingenew’s ongoing expansion of scientific data as well as the development of new clinical data will provide further evidence of Hesperco’s™ effectiveness in providing support for the immune system”

Commenting on its partnership with Valeo for Hesperco™, Pierre Laurin, President and CEO of Ingenew, said: “There is a strong scientific and medical rationale for the use of Hesperco™ capsules to support the immune system and potentially fight off symptoms associated with coronaviruses such as the one that causes COVID-19. Thousands of compounds have been evaluated since the start of the pandemic and the active compound in Hesperco™ capsules has been repeatedly reported to be one of the best candidate to interfere with the mechanisms SARS-CoV-2 uses to infect our cells. Furthermore, the modulation, by active compound in Hesperco™, of multiple inflammatory mediators has long been recognized in the scientific literature and it may play an important role in controlling potentially the exuberant inflammatory response or cytokine storm observed in severely affected patients. Our scientists’ review and analysis of the extensive amount of data



VALEO PHARMA™

published which support the potential benefits of Hesperco™ in COVID-19 has provided the basis for the development of Hesperco™ clinical strategy and program”.

About Ingenew Pharmaceuticals Inc.

Ingenew Pharma is a biopharmaceutical company focused on addressing unmet medical needs and serving patients and families affected by serious and debilitating illness. Its primary therapeutic areas of interest include oncology, neurology, urology and dermatology. Ingenew’s current research and development efforts are evaluating proprietary preparations and delivery systems designed to improve the clinical efficacy and reduce toxicity and side effects associated with standard of care. At Ingenew Pharma, we leverage the extensive and successful track record of our scientists and apply adaptive-creative research & development principles to advance tangible and affordable medical solutions, Hesperco™ being a good example. Hesperco™ is a trade mark owned by Ingenew Pharma and used by Valeo Pharma under a license agreement. (www.ingenewpharma.com)

About Valeo Pharma

Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on [LinkedIn](#) and [Twitter](#).

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For more information:

Valeo Pharma



VALEO PHARMA™

Steve Saviuk
President and CEO
514 693-8830
saviuk@valeopharma.com

Or

Frederic Dumais
Director Communications and Investor Relations
514-782-8803
dumais@valeopharma.com